Abstract:BACKGROUND:How the gut microbiota regulates intestinal homeostasis is not completely clear. Gut microbiota metabolite short-chain fatty acids (SCFAs) have been reported to regulate T-cell differentiation. However, the mechanisms underlying SCFA regulation of T-cell differentiation and function remain to be investigated.METHODS:CBir1, an immunodominant microbiota antigen, transgenic T cells were treated with butyrate under various T-cell polarization conditions to investigate butyrate regulation of T-cell differentiation and the mechanism involved. Transfer of butyrate-treated CBir T cells into Rag1-/- mice was performed to study the in vivo role of such T cells in inducing colitis.RESULTS:Although butyrate promoted Th1 cell development by promoting IFN-γ and T-bet expression, it inhibited Th17 cell development by suppressing IL-17, Rorα, and Rorγt expression. Interestingly, butyrate upregulated IL-10 production in T cells both under Th1 and Th17 cell conditions. Furthermore, butyrate induced T-cell B-lymphocyte-induced maturation protein 1 (Blimp1) expression, and deficiency of Blimp1 in T cells impaired the butyrate upregulation of IL-10 production, indicating that butyrate promotes T-cell IL-10 production at least partially through Blimp1. Rag1-/- mice transferred with butyrate-treated T cells demonstrated less severe colitis, compared with transfer of untreated T cells, and administration of anti-IL-10R antibody exacerbated colitis development in Rag-/- mice that had received butyrate-treated T cells. Mechanistically, the effects of butyrate on the development of Th1 cells was through inhibition of histone deacetylase but was independent of GPR43.CONCLUSIONS:These data indicate that butyrate controls the capacity of T cells in the induction of colitis by differentially regulating Th1 and Th17 cell differentiation and promoting IL-10 production, providing insights into butyrate as a potential therapeutic for the treatment of inflammatory bowel disease.

Butyrate Shapes Immune Cell Fate and Function in Allergic Asthma

Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells’ Differentiation and Function in Induction of Colitis

Short‐chain Fatty Acids Regulate B Cells Differentiation Via the FFA2 Receptor to Alleviate Rheumatoid Arthritis

Regulation of type 2 innate lymphoid cell-dependent airway hyperreactivity by butyrate

Microbial intestinal dysbiosis drives long-term allergic susceptibility by sculpting an ILC2-B1 cell-innate IgE axis

The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease

Short-chain fatty acids: linking diet, the microbiome and immunity

The nutrition-gut microbiome-physiology axis and allergic diseases

Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI‐mediated signaling

SCFA: mechanisms and functional importance in the gut

Butyrate: Connecting the gut-lung axis to the management of pulmonary disorders

Exploring the Molecular Mechanisms Underlying the Protective Effects of Microbial SCFAs on Intestinal Tolerance and Food Allergy

Maternal microbiome regulation prevents early allergic airway diseases in mouse offspring

Short-chain fatty acid-mediated epigenetic modulation of inflammatory T cells in vitro

Butyrate Properties in Immune-Related Diseases: Friend or Foe?

Short-chain fatty acid - A critical interfering factor for allergic diseases

Editorial: The interplay between microbiota and allergen in shaping respiratory mucosa immunity: Role in development of asthma

Influence and effect of the human microbiome in allergy and asthma

A new paradigm for a new simple chemical: butyrate & immune regulation

The gut microbiota modulates airway inflammation in allergic asthma through the gut-lung axis related immune modulation: A review

Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids